Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 19;13:1569–1581. doi: 10.2147/OTT.S237307

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Sun et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

miR-940 could target MAPK1.

Notes: (A) The sequences of MAPK1 3ʹUTR containing the miR-940 binding sites or mutant binding sites were shown. (B) The interaction between miR-940 and MAPK1 in TPC-1 and HTH83 cells was assessed by dual-luciferase reporter assay. (C and D) The mRNA and protein expression levels of MAPK1 in TC tissues (TC) and adjacent normal tissues (Normal) were determined by q-PCR and WB analysis. (E) WB analysis was used to measure the MAPK1 protein level in TC cells (TPC-1 and HTH83) and NTHY-ORI3.1 cells. (F) The expression of miR-940 was detected by q-PCR to evaluate the transfection efficiency of anti-miR-940. (G) The effects of miR-940 mimic and inhibitor on the protein level of MAPK1 in TPC-1 and HTH83 cells were measured by WB analysis. *P < 0.05.